A medical cannabis company in Israel has launched the first-of-a-kind products designed to help specific symptoms.
Israel’s largest medical cannabis company, Bazelet, has announced a breakthrough in medical cannabis products, launching multiple lines of terpene-enriched cannabis oils specifically designed for one of various indications and symptoms.
Its terpene-enriched products are optimised for personal needs such as women’s health, specific types of pain – such as muscle, joint, neuropathic – improved night’s sleep and elderly population concerns.
The company has invented a unique way of formulating medical cannabis oils that doesn’t depend on developing new strains in order to form a large variety of better-performing new oils.
It’s TOP technology generates improved new oils by blending extracts and by controlling their terpene content, particularly by enriching with scientific-based terpenes selection.
Bazelet’s scientific arm has devoted the last four years to finding which terpenes improve the performance of the cannabis oil for each indication or symptom and which ones have a negative effect.
Analysis of big data from hundreds of thousands of users, careful study of pre-clinical and clinical data and a deep dive into mechanisms of action, has resulted in these new formulations specifically designed for different indications.
Almost everyone is aware of Indica and Sativa strains, believed to be more suitable for night use and for day use, respectively. What is less known is that the majority of the terpenes responsible for the difference between the Indica nature and the Sativa nature are lost in the oil manufacturing.
Bazelet enriches its oils with the lost terpenes and further improvement is gained by enriching with selected terpenes, for example enriching Sativa oils with terpenes that increase focus and alertness, making it more suitable for day function.
Cannabis inflorescence contains 10-20 different terpenes, varying in amount and proportion and determining the characteristic aroma of the various strains.
Terpenes play an important medical role, individually and more importantly, in modulating the activity of the cannabinoids in the cannabis oil.
The terpene content of Bazelet oils is said to be 50-100 percent greater than those of common cannabis oils and are therefore referred to as terpenes-enriched.
Bazelet has filed around a dozen patent application families to protect its terpenes-enriched formulations and is ready to supply patent-protected terpenes blends to be added to extracts produced elsewhere in the world.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure